McDonald Andrew M, Fiveash John B, Kirkland Robert S, Cardan Rex A, Jacob Rojymon, Kim Robert Y, Dobelbower Michael C, Yang Eddy S
Department of Radiation Oncology, University of Alabama at Birmingham, Hazelrig-Salter Radiation Oncology Center, Birmingham, AL.
Department of Radiation Oncology, University of Alabama at Birmingham, Hazelrig-Salter Radiation Oncology Center, Birmingham, AL.
Urol Oncol. 2017 Nov;35(11):663.e15-663.e21. doi: 10.1016/j.urolonc.2017.07.012. Epub 2017 Aug 7.
PURPOSE/OBJECTIVE(S): To assess subcutaneous adipose tissue characteristics by computed tomography (CT) as potential imaging biomarkers predictive of biochemical recurrence in men with high-risk prostate cancer receiving radiotherapy (RT).
This retrospective study included men with high-risk prostate cancer (PSA>20ng/ml, Gleason score ≥8, or clinical extraprostatic extension) treated between 2001 and 2012. All patients received definitive, dose-escalated external beam RT along with a course of neoadjuvant, concurrent, and adjuvant androgen deprivation therapy (ADT). Each patient also had a treatment planning CT that included the L4-L5 vertebral interface and prostate specific antigen (PSA) measurements for at least 2 years following RT. The subcutaneous adipose tissue was contoured on a single axial CT slice at the level of L4-L5. The average CT attenuation, in Hounsfield units (HU), of the structure was calculated and defined as SAT. SAT was defined as the cross-sectional area of the structure (in cm) that was then normalized by the square of patient height. Biochemical failure (BF) was defined as a PSA rise of 2ng/ml from the nadir. Freedom from BF (FFBF) was calculated from start time of ADT using the Kaplan-Meier method. Estimates of FFBF were stratified by SAT and SAT quartiles.
A total of 171 men met the inclusion criteria with a median follow-up of 5.6 years. The mean SAT (±standard deviation) was -99.2HU (±6.1HU), and the mean SAT was 93.2cm/m (±39.4cm/m). The 5- and 8-year rates of FFBF across all patients were 81.5% and 73.5%, respectively. Patients in the lowest quartile of SAT experienced significantly higher FFBF compared to the other quartiles (Q4 vs. Q1, P = 0.017; Q4 vs. Q2, P = 0.045; Q4 vs. Q3, P = 0.044). No other differences in FFBF were observed between quartiles of SAT or other quartiles of SAT.
Lower subcutaneous adipose tissue density was associated with a lower rate of BF following RT with ADT for men with high-risk prostate cancer. Further research is needed to elucidate the biological underpinnings of this clinical finding and the role adipose tissue plays in modulating oncologic behavior and outcomes.
通过计算机断层扫描(CT)评估皮下脂肪组织特征,作为预测接受放疗(RT)的高危前列腺癌男性生化复发的潜在影像生物标志物。
这项回顾性研究纳入了2001年至2012年间接受治疗的高危前列腺癌男性患者(前列腺特异性抗原[PSA]>20ng/ml、 Gleason评分≥8或临床前列腺外侵犯)。所有患者均接受了确定性、剂量递增的外照射放疗以及新辅助、同步和辅助雄激素剥夺治疗(ADT)疗程。每位患者在放疗后至少2年还进行了包含L4-L5椎体界面的治疗计划CT扫描和PSA测量。在L4-L5水平的单个轴向CT切片上勾勒出皮下脂肪组织。计算该结构以亨氏单位(HU)表示的平均CT衰减,并将其定义为SAT。SAT定义为该结构的横截面积(以平方厘米为单位),然后通过患者身高的平方进行归一化。生化失败(BF)定义为PSA从最低点升高2ng/ml。使用Kaplan-Meier方法从ADT开始时间计算无生化失败生存期(FFBF)。FFBF估计值按SAT和SAT四分位数进行分层。
共有171名男性符合纳入标准,中位随访时间为5.6年。平均SAT(±标准差)为-99.2HU(±6.1HU),平均SAT为93.2cm/m²(±39.4cm/m²)。所有患者的5年和8年FFBF率分别为81.5%和73.5%。SAT最低四分位数的患者与其他四分位数相比,FFBF明显更高(Q4与Q1相比,P = 0.017;Q4与Q2相比,P = 0.045;Q4与Q3相比,P = 0.044)。在SAT四分位数之间或SAT的其他四分位数之间未观察到FFBF的其他差异。
对于接受ADT放疗的高危前列腺癌男性,较低的皮下脂肪组织密度与较低的BF发生率相关。需要进一步研究以阐明这一临床发现的生物学基础以及脂肪组织在调节肿瘤行为和结局中所起的作用。